Supplemental Online Content

Longenecker CT, Jones KA, Hileman CO, et al. Nurse-led strategy to improve blood pressure and cholesterol level among people with HIV: a randomized clinical trial. *JAMA Netw Open*. 2024;7(3):e2356445. doi:10.1001/jamanetworkopen.2023.56445

eFigure 1. Study Accrual

eTable 1. Characteristics of People with HIV Who Consented to Participate in EXTRA-CVD Compared to Those Who Declined Participation After an Initial Phone Screen

eTable 2. Patient Blood Pressure and Cholesterol Values at Baseline, Overall and by Treatment Arm

eFigure 2. Stacked Bar Chart of Blood Pressure Values at Baseline, by Anti-Hypertensive Treatment Status

eTable 3. Model-Estimated Outcome Means and Standard Errors or Proportions by Study Arm and Time Point

eTable 4. Testing Sex as a Moderator of the Intervention Effects on Outcomes by Including an Interaction Term Between Study Arm, Study Visit, and Sex, With Male Sex Compared to Female (Reference Group)

eTable 5. Testing ASCVD Risk as a Moderator of the Intervention Effects on Outcomes by Including an Interaction Term Between Study Arm, Study Visit, and ASCVD Risk, With High ASCVD Risk Compared to Low/Moderate Risk (Reference Group)


eTable 6. Testing Site as a Moderator of the Intervention Effects on Outcomes by Including an Interaction Term Between Study Arm, Study Visit, and Site, With Sites 2 and 3 Compared to Site 1 (Reference Group)

eTable 7. Intervention Effects Stratified by Treating Physician (EXTRA-CVD Investigator or Not)

eTable 8. Adverse Events by Treatment Arm

eTable 9. Sensitivity Analysis of Intervention Effects on Primary, Secondary, and Tertiary Outcomes, Adjusted for Baseline Covariates Associated With Attrition

This supplemental material has been provided by the authors to give readers additional information about their work.



eFigure 1. Study Accrual

acceptable levels.

eTable 1. Characteristics of People with HIV Who Consented to Participate in EXTRA-CVD Compared to Those Who Declined Participation After an Initial Phone Screen

	Consented to	Did not consent	
	participate in	to participate in	
Variable	EXTRA-CVD	EXTRA-CVD	p-value
N	299 ^b	106	-
<u>Demographics</u>			
Age (years), Mean (SD)	57.3 (9.6)	53.4 (11.4)	.003
Age (years), Median (Q1, Q3)	59.0 (52.0, 64.0)	56.0 (45.0, 62.0)	.003
Gender			.29
Male	234 (78.3%)	80 (75.5%)	
Female	62 (20.7%)	23 (21.7%)	
Transgender Male/Transman/FTM	1 (0.3%)	0 (0.0%)	
Transgender Female/Transwoman/MTF	2 (0.7%)	1 (0.9%)	
Other gender	0 (0.0%)	1 (0.9%)	
Unreported	0 (0.0%)	1 (0.9%)	
Sex			.85
Female	62 (20.7%)	23 (21.7%)	
Male	232 (77.6%)	82 (77.4%)	
Unreported	5 (1.7%)	1 (0.9%)	
Hispanic or Latino ethnicity			.003
Non-Hispanic	281 (94.0%)	101 (95.3%)	
Hispanic/Latino	17 (5.7%)	1 (0.9%)	
Unreported	1 (0.3%)	4 (3.8%)	
Race			.04
African American/Black	181 (60.5%)	65 (61.3%)	
American Indian/Alaskan Native	0 (0.0%)	1 (0.9%)	
White	100 (33.4%)	35 (33.0%)	
Other race	9 (3.0%)	1 (0.9%)	
Multiracial	7 (2.3%)	0 (0.0%)	
Unknown	2 (0.7%)	4 (3.8%)	


^a This table includes all patients who were deemed eligible for EXTRA-CVD following the medical record review and participant screening. Demographic information was collected at the participant screening, as approved by the IRB.


^b As shown in Figure 1 of the manuscript, n=299 is two higher than the n=297 who were included in the final analysis. One participant withdrew after consent but prior to randomization; another participant withdrew after randomization but prior to the baseline visit.

	Overall	Intervention	Control
Variable	N=297	N=149	N=148
Blood Pressure			
Systolic blood pressure, Mean (SD)	135.0 (18.8)	135.9 (18.1)	134.0 (19.5)
Diastolic blood pressure, Mean (SD)	81.1 (12.1)	81.2 (12.2)	81.0 (12.0)
<u>Cholesterol</u>			
Total cholesterol, Mean (SD)	184.7 (46.1)	185.1 (45.3)	184.4 (46.9)
LDL, Mean (SD)	111.8 (39.6)	111.5 (38.6)	112.1 (40.6)
HDL, Mean (SD)	45.2 (14.5)	45.8 (14.7)	44.7 (14.3)
Non-HDL, Mean (SD)	139.9 (44.6)	139.5 (44.6)	140.3 (44.9)
Triglycerides, Median (Q1, Q3) ^a	121.0 (89.0, 184.0)	127.0 (95.0, 182.0)	112.0 (85.0, 191.0)

eTable 2. Patient Blood Pressure and Cholesterol Values at Baseline, Overall and by Treatment Arm

^aMedian (Q1, Q3) presented due to skewness of the data





eTable 3. Model-Estimated Outcome Means and Standard Errors or Proportions by Study Arm and Time Point

	Base	eline	4 mo	nths	8 mo	onths	12 m	onths
Outcomes	Intervention estimate Mean (SE) ^a	Control estimate Mean (SE) ^a						
Primary outcome			I		L		L	
Systolic blood pressure, mm Hg	134.9 (1.0)	134.9 (1.0)	129.9 (1.5)	136.3 (1.5)	129.3 (1.6)	133.0 (1.4)	129.7 (1.5)	133.9 (1.4)
Secondary outcome			ļ		1		1	
Non-HDL cholesterol, mg/dL	139.9 (2.5)	139.9 (2.5)	127.4 (3.5)	135.7 (3.4)	120.9 (3.5)	131.9 (3.3)	114.7 (3.5)	132.1 (3.3)
Tertiary outcomes			ļ		1		1	
Hypertension treatment cascade ^b	%	%	%	%	%	%	%	%
Untreated	10.8%	10.8%	7.8%	9.9%	3.2%	7.7%	5.7%	11.6%
Treated	47.3%	47.3%	34.3%	45.7%	33.2%	45.3%	34.4%	48.6%
At treatment goal	42.0%	42.0%	57.9%	44.4%	63.6%	47.0%	59.9%	39.8%
Hypercholesterolemia treatment cascade ^b	%	%	%	%	%	%	%	%
Untreated	37.5%	37.5%	18.1%	27.5%	5.9%	16.3%	5.3%	27.1%
Treated	20.5%	20.5%	15.7%	18.0%	9.0%	16.3%	3.6%	14.1%
At treatment goal	42.0%	42.0%	66.3%	54.5%	85.1%	67.4%	91.1%	58.7%
Exploratory outcomes			I		I		I	
Total cholesterol, mg/dL	184.9 (2.6)	184.9 (2.6)	172.4 (3.6)	179.9 (3.5)	165.8 (3.6)	176.4 (3.4)	161.5 (3.6)	177.5 (3.4)
HDL cholesterol, mg/dL	45.4 (0.9)	45.4 (0.9)	45.2 (1.1)	44.3 (1.0)	45.1 (1.1)	43.5 (1.0)	46.4 (1.1)	45.6 (1.0)
LDL cholesterol, mg/dL	111.5 (3.7)	111.5 (3.7)	107.4 (5.9)	115.4 (5.7)	93.3 (6.0)	104.7 (5.5)	96.4 (5.9)	107.0 (5.6)
Triglycerides, mg/dL	165.7 (7.7)	165.7 (7.7)	152.6 (10.4)	163.7 (10.1)	136.6 (10.5)	169.2 (9.8)	133.6 (10.5)	161.6 (9.9)

^aUnless noted otherwise

^bCategorized into one of the three mutually exclusive categories: untreated (regardless of whether it has been diagnosed), appropriately managed (at least one prescribed medication for hypertension/hypercholesterolemia), or at treatment goal (<130 systolic blood pressure for hypertension and <130 or <100 mg/dL, depending on risk score, for hypercholesterolemia)

eTable 4. Testing Sex as a Moderator of the Intervention Effects on Outcomes by Including an Interaction Term Between Study Arm, Study Visit, and Sex, With Male Sex Compared to Female (Reference Group)

			Ir	ntervention effect			
Outcomes	Overall joint test	4 months		8 months		12 months	
	р	Beta (95% CI)	р	Beta (95% CI)	р	Beta (95% CI)	р
Primary outcome			·				·
Systolic blood pressure, mm Hg	.06	11.8 (2.0, 21.6)	.02	9.6 (-0.1, 19.3)	.05	5.9 (-3.8, 15.5)	.23
Secondary outcome			·				
Non-HDL cholesterol, mg/dL	.70	-11.1 (-31.6, 9.4)	.29	0.1 (-20.1, 20.4)	.99	0.4 (-19.9, 20.7)	.97
Tertiary outcomes							
Hypertension treatment cascade	.81						
Treated		1.4 (0.1, 16.1)	.77	0.5 (0.0, 9.0)	.61	0.5 (0.0, 6.5)	.60
At treatment goal		0.4 (0.0, 4.8)	.49	0.3 (0.0, 4.6)	.35	0.8 (0.1, 9.2)	.85
Hypercholesterolemia treatment cascade	.80						
Treated		1.9 (0.1, 34.7)	.68	0.6 (0.0, 14.3)	.73	0.1 (0.0, 3.0)	.20
At treatment goal		4.2 (0.3, 61.5)	.30	1.2 (0.1, 18.2)	.90	0.5 (0.0, 6.7)	.56
Exploratory outcomes			·				
Total cholesterol, mg/dL	.58	-12.7 (-33.5, 8.2)	.23	2.5 (-18.1, 23.1)	.81	-4.8 (-25.4, 15.9)	.65
HDL cholesterol, mg/dL	.36	-2.5 (-8.1, 3.0)	.37	0.9 (-4.6, 6.4)	.75	-3.8 (-9.3, 1.7)	.18
LDL cholesterol, mg/dL	.93	-7.5 (-46.7, 31.7)	.71	5.6 (-33.2, 44.3)	.78	8.0 (-30.9, 46.9)	.69

			J	Intervention effect				
Outcomes	Overall joint test	4 months		8 months		12 months		
	р	Beta (95% CI)	р	Beta (95% CI)	р	Beta (95% CI)	р	
Triglycerides, mg/dL	.40	2.0 (-57.6, 61.5)	.95	-47.1 -106.0, 11.9)	.12	-7.7 (-66.7, 51.3)	.80	

Overall joint test tests whether there is an overall moderating effect by sex

eTable 5. Testing ASCVD Risk as a Moderator of the Intervention Effects on Outcomes by Including an Interaction Term Between Study Arm, Study Visit, and ASCVD Risk, With High ASCVD Risk Compared to Low/Moderate Risk (Reference Group)

				Intervention effect			
Outcomes	Overall joint test					12 months	
	р	Beta (95% CI)	р	Beta (95% CI)	р	Beta (95% CI)	р
Primary outcome							
Systolic blood pressure, mm Hg	.24	-6.3 (-14.9, 2.3)	.15	-7.9 (-16.3, 0.6)	.07	-3.5 (-12.0, 5.0)	.42
Secondary outcome							
Non-HDL cholesterol, mg/dL	.53	5.1 (-12.5, 22.6)	.57	13.0 (-4.3, 30.4)	.14	5.5 (-12.0, 23.1)	.54
Tertiary outcomes							
Hypertension treatment cascade	.31						
Treated		1.8 (0.1, 24.0)	.65	0.8 (0.0, 17.5)	.89	0.3 (0.0, 3.6)	.33
At treatment goal		4.2 (0.3, 51.2)	.26	2.2 (0.1, 44.0)	.61	2.5 (0.2, 29.2)	.47
Hypercholesterolemia treatment cascade	.30						
Treated		11.4 (0.9, 147.7)	.06	6.2 (0.4, 99.2)	.20	3.1 (0.2, 62.3)	.45
At treatment goal		1.7 (0.2, 17.7)	.65	2.9 (0.2, 36.0)	.40	6.4 (0.5, 91.1)	.17
Exploratory outcomes							
Total cholesterol, mg/dL	.66	2.8 (-15.1, 20.7)	.76	11.3 (-6.5, 29.0)	.21	4.4 (-13.5, 22.3)	.63
HDL cholesterol, mg/dL	.46	-1.7 (-6.5, 3.2)	.50	-2.6 (-7.4, 2.2)	.30	-3.8 (-8.6, 1.0)	.12
LDL cholesterol, mg/dL	.12	38.9 (4.5, 73.4)	.03	12.9 (-21.0, 46.8)	.46	-9.6 (-44.1, 25.0)	.59

				Intervention effect			
Outcomes	Overall joint test	4 months		8 months		12 months	
	р	Beta (95% CI)	р	Beta (95% CI)	р	Beta (95% CI)	р
Triglycerides, mg/dL	.63	13.0 (-34.3, 60.3)	.59	13.1 (-33.8, 59.9)	.58	31.7 (-15.5, 79.0)	.19

Overall joint test tests whether there is an overall moderating effect by ASCVD risk

eTable 6. Testing Site as a Moderator of the Intervention Effects on Outcomes by Including an Interaction Term Between Study Arm, Study Visit, and Site, With Sites 2 and 3 Compared to Site 1 (Reference Group)

				Intervention effect			
Outcomes	Overall joint test	4 months		8 months		12 months	
	р	Beta (95% CI)	р	Beta (95% CI)	р	Beta (95% CI)	р
Primary outcome					ľ		
Systolic blood pressure, mm Hg	.70		.57		.80		.42
SBP, Site B		2.8 (-6.7, 12.3)	.57	-2.6 (-12.1, 7.0)	.59	-4.6 (-14.1, 4.9)	.34
SBP, Site C		-2.7 (-12.6, 7.3)	.60	0.5 (-9.3, 10.2)	.92	-6.3 (-16.2, 3.6)	.21
Secondary outcome					ľ		
Non-HDL cholesterol, mg/dL	.82		.93		.93		.39
Non-HDL, Site B		1.0 (-18.8, 20.8)	.92	-3.0 (-23.0, 16.9)	.77	13.9 (-6.0, 33.8)	.17
Non-HDL, Site C		3.9 (-17.0, 24.8)	.72	-3.5 (-23.9, 17.0)	.74	7.4 (-13.3, 28.1)	.48
Tertiary outcomes					ľ		
Hypertension treatment cascade	.91		.84		.53		.74
Treated, Site B		Not est.	.94	0.8 (0.0, 30.5)	.90	Not est.	.98
Treated, Site C		Not est.	.94	0.5 (0.0, 12.5)	.64	Not est.	.98
At treatment goal, Site B		Not est.	.93	3.9 (0.1, 138.9)	.45	Not est.	.99
At treatment goal, Site C		Not est.	.94	1.3 (0.1, 32.5)	.86	Not est.	.98

		Intervention effect										
Outcomes	Overall joint test	4 months		8 months		12 months						
	р	Beta (95% CI)	р	Beta (95% CI)	р	Beta (95% CI)	р					
Hypercholesterolemia treatment cascade	.12		.95		.91		.01					
Treated, Site B		0.9 (0.0, 21.4)	.92	1.3 (0.0, 43.0)	.88	61.3 (1.5, 2423.9)	.03					
Treated, Site C		2.8 (0.1, 69.3)	.54	0.3 (0.0, 11.5)	.52	0.6 (0.0, 23.1)	.76					
At treatment goal, Site B		1.3 (0.1, 22.7)	.86	1.7 (0.1, 41.1)	.75	0.5 (0.0, 11.0)	.64					
At treatment goal, Site C		2.1 (0.1, 39.5)	.62	0.6 (0.0, 14.6)	.77	0.2 (0.0, 4.3)	.33					
Exploratory outcomes												
Total cholesterol, mg/dL	.98		.98		.93		.74					
Total cholesterol, Site B		-1.5 (-21.7, 18.7)	.88	-3.5 (-23.9, 16.8)	.73	7.3 (-13.0, 27.6)	.48					
Total cholesterol, Site C		0.2 (-21.0, 21.5)	.98	-3.1 (-23.9, 17.7)	.77	6.6 (-14.4, 27.7)	.54					
HDL cholesterol, mg/dL	.02		.41		.84		.009					
HDL, Site B		-2.9 (-8.2, 2.5)	.29	1.5 (-3.9, 6.9)	.59	-8.0 (-13.3, -2.6)	.004					
HDL, Site C		-3.5 (-9.1, 2.2)	.23	1.3 (-4.2, 6.8)	.64	-1.3 (-6.9, 4.3)	.64					
LDL cholesterol, mg/dL	.67		.66		.90		.17					
LDL, Site B		-1.6 (-38.9, 35.6)	.93	-2.6 (-40.4, 35.1)	.89	5.5 (-32.1, 43.0)	.78					
LDL, Site C		16.1 (-24.3, 56.4)	.44	6.5 (-32.6, 45.6)	.74	36.1 (-3.8, 76.0)	.08					
Triglycerides, mg/dL	.41		.29		.47		.89					
Triglycerides, Site B		-7.1 (-64.7, 50.6)	.81	-32.2 (-90.5, 26.0)	.28	14.1 (-43.9, 72.1)	.63					

			Intervention effect									
Outcomes	Overall joint test	4 months		8 months		12 months						
	р	Beta (95% CI)	р	Beta (95% CI)	р	Beta (95% CI)	р					
Triglycerides, Site C		39.8 (-21.0, 100.7)	.20	-31.0 (-90.6, 28.5)	.31	8.1 (-52.1, 68.4)	.79					

Overall joint test tests whether there is an overall moderating effect by site. Not est. = not estimable, valid estimates not available in some of the multinomial regression models

					Int	terven	tion effects					
		4 ma	onths			8 m	onths			12 m	onths	
Outcomes	Study cli	nician	None		Study clini	cian	None		Study clin	nician	Non	e
	Beta		Beta		Beta		Beta		Beta		Beta	
	(95% CI)	р	(95% CI)	р	(95% CI)	р	(95% CI)	р	(95% CI)	р	(95% CI)	р
Primary outcome												
Systolic blood pressure,	-7.3	.09	-5.6	.01	-10.3	.01	-1.0	.67	3.6	.39	-6.3	.006
mm Hg	(-15.8, 1.2)		(-10.1, -1.2)		(-18.6, -2.0)		(-5.4, 3.5)		(-4.7, 11.8)		(-10.7, - 1.9)	
Secondary outcome	•											
Non-HDL cholesterol,	-14.9	.11	-5.7	.23	-12.2	.19	-10.3	.03	-14.6	.11	-17.6	<.001
mg/dL	(-33.5, 3.6)		(-15.0, 3.6)		(-30.4, 5.9)		(-19.5, -1.0)		(-32.7, 3.5)		(-26.9, - 8.4)	
Tertiary outcomes	1								•			
Hypertension treatment	OR		OR		OR		OR		OR		OR	
cascade	(95% CI)	р	(95% CI)	p	(95% CI)	р	(95% CI)	р	(95% CI)	р	(95% CI)	р
Treated	Not est.	<.001	0.5	.27	Not est.	.82	1.4	.61	Not est.	<.001	1.1	.90
			(0.1, 1.7)				(0.4, 5.8)				(0.3, 3.6)	
At treatment goal	Not est.	<.001	1.2	.76	Not est.	.81	2.0	.31	Not est.	<.001	2.5	.12
			(0.4, 3.7)				(0.5, 7.5)				(0.8, 8.0)	
Hypercholesterolemia	OR		OR		OR		OR		OR		OR	
treatment cascade	(95% CI)	p	(95% CI)	р	(95% CI)	р	(95% CI)	р	(95% CI)	р	(95% CI)	р
Treated	0.7	.79	1.5	.57	1.9	.65	1.4	.67	1.3	.85	1.1	.91
	(0.1, 9.6)		(0.4, 6.6)		(0.1, 27.1)		(0.3, 7.1)		(0.1, 21.1)		(0.2, 5.9)	
At treatment goal	1.4	.79	1.7	.41	15.2	.05	2.0	.31	7.7	.14	6.9	.004
	(0.1, 19.4)		(0.5, 5.5)		(1.0, 233.3)		(0.5, 7.5)		(0.5, 116.6)		(1.9, 25.7)	
Exploratory outcomes												

eTable 7. Intervention Effects Stratified by Treating Physician (EXTRA-CVD Investigator or Not)

					In	terven	tion effects					
		4 m	onths			8 m	onths			12 n	onths	
Outcomes	Study clinician		None		Study clini	cian	None		Study clin	ician	Non	e
	Beta		Beta		Beta		Beta		Beta		Beta	
	(95% CI)	р	(95% CI)	р	(95% CI)	р	(95% CI)	р	(95% CI)	р	(95% CI)	р
Total cholesterol, mg/dL	-10.3	.30	-6.2	.19	-9.5	.32	-10.4	.03	-11.4	.24	-16.7	<.001
	(-29.7, 9.1)		(-15.6, 3.1)		(-28.5, 9.5)		(-19.7, -1.1)		(-30.4, 7.5)		(-26.1, -	
											7.4)	
HDL cholesterol, mg/dL	3.3	.12	0.1	.93	1.5	.47	1.9	.17	2.3	.26	0.4	.77
-	(-0.9, 7.5)		(-2.6, 2.8)		(-2.6, 5.6)		(-0.8, 4.5)		(-1.8, 6.5)		(-2.3, 3.1)	
LDL cholesterol, mg/dL	-12.4	.13	-1.1	.91	-7.0	.39	-7.1	.49	-9.8	.23	-4.3	.68
	(-28.6, 3.8)		(-21.5, 19.3)		(-23.1, 9.0)		(-27.3, 13.0)		(-25.7, 6.1)		(-24.7,	
	, , , , , , , , , , , , , , , , , , ,				· · · /						16.1)	
Triglycerides, mg/dL	-15.3	.59	-9.9	.47	-49.0	.08	-28.8	.03	-22.1	.43	-30.5	.03
	(-71.0,		(-36.7, 17.0)		-103.7, 5.7)		(-55.4, -2.1)		(-76.8,		(-57.3, -	
	40.4)		、 <i>, ,</i>				. , ,		32.6)		3.7)	

Not est. = not estimable, valid estimates not available in some of the multinomial regression models

eTable 8. Adverse Events by Treatment Arm

Variable	EXTRA-CVD Intervention	Education Control 148 55 (37.2%)	
N, total number of participants	149		
Total participants with ≥1 AE	60 (40.3%)		
Number of AE per participant, among all participants			
Mean (SD)	0.7 (1.2)	0.8 (1.6)	
Median (Q1, Q3)	0 (0, 1)	0 (0, 1)	
Number of AE per participant, among those with ≥ 1 AE			
Mean (SD)	1.8 (1.2)	2.3 (1.9)	
Median (Q1, Q3)	1 (1, 2)	2 (1, 3)	
N, total number of adverse events	107	125	
Serious AE	47 (43.9%)	47 (37.6%)	
AE unexpected	39 (36.4%)	44 (35.2%)	
AE grade			
Mild (Grade 1)	11 (10.3%)	12 (9.6%)	
Moderate (Grade 2)	30 (28.0%)	44 (35.2%)	
Severe (Grade 3)	56 (52.3%)	53 (42.4%)	
Life-threatening (Grade 4)	8 (7.5%)	14 (11.2%)	
Death (Grade 5)	2 (1.9%)	2 (1.6%)	
AE related to study			
Not related	81 (75.7%)	96 (76.8%)	
Unlikely to be related	22 (20.6%)	26 (20.8%)	
Possibly related	1 (0.9%) 3 (2.4%)		
Probably related	2 (1.9%)	0 (0.0%)	
Definitely related	1 (0.9%)	0 (0.0%)	

AE, adverse event

	Intervention effect						
Outcomes	4 months		8 months		12 months		
Primary outcome	Beta (95% CI)	р	Beta (95% CI)	р	Beta (95% CI)	р	
Systolic blood pressure, mm Hg	-5.7 (-9.7, -1.7)	.005	-3.1 (-7.0, 0.9)	.13	-3.6 (-7.5, 0.4)	.08	
Secondary outcome	Beta (95% CI)	р	Beta (95% CI)	р	Beta (95% CI)	р	
Non-HDL cholesterol, mg/dL	-8.7 (-17.1, -0.4)	.04	-11.2 (-19.5, -2.9)	.008	-17.6 (-25.9, - 9.4)	< .001	
Tertiary outcomes	OR (95% CI)	р	OR (95% CI)	р	OR (95% CI)	р	
Hypertension treatment cascade							
Treated	0.9 (0.3, 2.6)	.80	1.5 (0.4, 5.6)	.50	1.2 (0.4, 3.8)	.70	
At treatment goal	1.3 (0.5, 3.7)	.61	2.6 (0.7, 8.9)	.14	2.4 (0.8, 6.9)	.12	
Hypercholesterolemia treatment cascade							
Treated	1.4 (0.4, 4.8)	.55	1.6 (0.4, 5.8)	.51	1.3 (0.3, 5.2)	.68	
At treatment goal	2.0 (0.7, 6.0)	.20	3.8 (1.2, 12.2)	.03	8.8 (2.7, 28.2)	< .001	
Exploratory outcomes	Beta (95% CI)	р	Beta (95% CI)	р	Beta (95% CI)	р	
Total cholesterol, mg/dL	-6.6 (-14.8, 1.5)	.11	-9.4 (-17.5, -1.3)	.02	-15.2 (-23.4, - 7.1)	< .001	
HDL cholesterol, mg/dL	1.1 (-1.2, 3.3)	.36	1.8 (-0.4, 4.1)	.11	1.0 (-1.2, 3.3)	.37	
LDL cholesterol, mg/dL	-8.0 (-23.9, 7.8)	.32	-11.4 (-27.0, 4.1)	.15	-11.0 (-26.7, 4.7)	.17	
Triglycerides, mg/dL	-12.4 (-36.5, 11.7)	.31	-34.3 (-58.1, - 10.5)	.005	-29.6 (-53.5, - 5.7)	.02	

eTable 9. Sensitivity Analysis of Intervention Effects on Primary, Secondary, and Tertiary Outcomes, Adjusted for Baseline Covariates Associated With Attrition^a

^a Covariates associated with attrition were race, ethnicity, smoking status, mental health history, insurance status, and employment status. Sex was added as an additional covariate given the results of the moderation analyses. Covariates were tested for multicollinearity before entering into the final model